Nabriva Therapeutics
Board news from biotech Nabriva, which develops pleuromutilins, a class of antibiotics for infections caused by resistant gram-positive and gram-negative pathogens.
The Vienna/Philadelphia-based company announced Charles Rowland has been appointed to its supervisory board and Steven Gelone will become Chief Development Officer and a member of the management team.
Rowland was VP and Chief Financial Officer of ViroPharma until its acquisition by Shire last year.
Gelone served as Head of Clinical Research and Development at Spark Therapeutics, and VP of Development at ViroPharma until it was acquired by Shire in January 2014. He has also held senior positions at GSK, Vicuron Pharmaceuticals and Temple University Schools of Pharmacy and Medicine.